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Continuous low-intensity ultrasound
attenuates IL-6 and TNFα-induced catabolic
effects and repairs chondral fissures in
bovine osteochondral explants
Neety Sahu1, Hendrik J. Viljoen1 and Anuradha Subramanian2*

Abstract
Background: Cartilage repair outcomes are compromised in a pro-inflammatory environment; therefore, the
mitigation of pro-inflammatory responses is beneficial. Treatment with continuous low-intensity ultrasound (cLIUS)
at the resonant frequency of 5 MHz is proposed for the repair of chondral fissures under pro-inflammatory
conditions.
Methods: Bovine osteochondral explants, concentrically incised to create chondral fissures, were maintained under
cLIUS (14 kPa (5 MHz, 2.5 Vpp), 20 min, 4 times/day) for a period of 28 days in the presence or absence of cytokines,
interleukin-6 (IL-6) or tumor necrosis factor (TNF)α. Outcome assessments included histological and
immunohistochemical staining of the explants; and the expression of catabolic and anabolic genes by qRT-PCR in
bovine chondrocytes. Cell migration was assessed by scratch assays, and by visualizing migrating cells into the
hydrogel core of cartilage-hydrogel constructs.
Results: Both in the presence and absence of cytokines, higher percent apposition along with closure of fissures
were noted in cLIUS-stimulated explants as compared to non-cLIUS-stimulated explants on day 14. On day 28, the
percent apposition was not significantly different between unstimulated and cLIUS-stimulated explants exposed to
cytokines. As compared to non-cLIUS-stimulated controls, on day 28, cLIUS preserved the distribution of
proteoglycans and collagen II in explants despite exposure to cytokines. cLIUS enhanced the cell migration
irrespective of cytokine treatment. IL-6 or TNFα-induced increases in MMP13 and ADAMTS4 gene expression was
rescued by cLIUS stimulation in chondrocytes. Under cLIUS, TNFα-induced increase in NF-κB expression was
suppressed, and the expression of collagen II and TIMP1 genes were upregulated.
Conclusion: cLIUS repaired chondral fissures, and elicited pro-anabolic and anti-catabolic effects, thus
demonstrating the potential of cLIUS in improving cartilage repair outcomes.
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Background
Repair of damaged cartilage remains a biomedical burden as
cartilage repair techniques such as microfracture, autologous
chondrocyte implantation (ACI) and grafting methods including tissue-engineered approaches have failed to generate
functional hyaline cartilage [1–3]. In addition to other factors
that influence in-vivo repair outcomes, initial stages of repair
typically take place in pro-inflammatory environment. A
pro-inflammatory environment compromises the repair efforts by promoting cartilage degeneration [4–6]. Consequently, the efficacy of current and upcoming regenerative
strategies is predicated on the mitigation of the detrimental
effects of a pro-inflammatory joint environment to improve
cartilage repair outcomes.
In an important study, the cytokine profile in patients with
symptomatic cartilage defects as well as osteoarthritis (OA)
revealed elevated levels of catabolic cytokines, including
interleukin (IL), − 6 and tumor necrosis factor (TNF) α, in
the synovial fluid and cartilage tissue extracts [7]. IL-6 and
TNFα were also elevated in both acute and chronic phases
of other joint injuries [7, 8]. IL-6 or TNFα-induced synthesis
of matrix-degrading enzymes, such as metallopeptidases
(MMPs) and A Disintegrin and Metalloproteinase with
Thrombospondin Motifs (ADAMTS) aggrecanases, has been
strongly implicated in cartilage degradation and OA pathogenesis [9]. Therefore, chondroprotective approaches that
mitigate the catabolic effects of the pro-inflammatory joint
environment are of interest.
Although the administration of non-steroidal anti-inflammatory drugs (NSAIDs) are the logical first-line treatment in
an inflamed joint, low intraarticular residence time and sideeffects including gastrointestinal ulcers and cardiotoxicity
necessitate alternative therapeutic efforts [10]. Recently the
chondroprotective effects of pLIUS against a potent catabolic
cytokine, IL-1β on intact cartilage explants was demonstrated in vitro [11]. However, to our knowledge, the chondroprotective effects of LIUS on other catabolic cytokines
that are elevated in injured cartilage and endogenously produced by the injured cartilage itself (IL-6 and TNFα) remains
uninvestigated. Further, the repair of chondral fissures under
cLIUS in the presence of catabolic cytokines has not been
investigated. Therefore, the current study investigated the
ability of continuous LIUS (cLIUS) to promote the repair of
chondral fissures in the presence of pro-inflammatory cytokines, IL-6 and TNFα, shown to be elevated in injured cartilage and sustained for weeks post-injury [7].
Our work has shown that at any given frequency, cLIUS
couples more energy than pLIUS [12] and that the
bio-effects of cLIUS are frequency dependent [12–14].
Hence, differently from previous studies that employ pLIUS
(1.5 MHz), our approach employed cLIUS at the cell resonant frequency of 5 MHz where the cLIUS-induced bioeffects were reportedly maximized [13, 14]. Further, cLIUS
at 5 MHz was shown to close chondral fissures by
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promoting anabolic response as evidenced by a
3.88-fold higher interfacial strength and the enhancement of the cartilage phenotype when compared to
controls in an in-vitro model of integration in osteochondral explant (data under peer-review). To extend
our promising findings to experimental conditions
that mimic a pro-inflammatory environment, the efficacy of cLIUS at 5 MHz in narrowing cartilage fissures while preserving the cartilage phenotype in the
presence of IL-6 or TNFα was evaluated. Our study
was predicated on the hypothesis that cLIUS enhances the cartilage phenotype, cellular migration and
inhibits the expression of catabolic markers by
suppressing NF-κB expression and upregulating the
expression of anabolic markers. Thus, bovine osteochondral explants with cylindrical incisions simulating fissures in the cartilage were cultured in a
cLIUS-assisted bioreactor developed at the University
of Nebraska-Lincoln (UNL) [15] in the presence or
absence of IL-6 or TNFα for a period of 28 days.
Outcome analyses included histological and immunohistochemical assessments of the explants coupled
with gene expression of catabolic and anabolic
markers.

Methods
Creation of chondral fissures in the osteochondral
explants and their culture

Bovine osteochondral explants (8 mm diameter, 1-2 mm
cartilage thickness and 5 mm bone segment) from stifle
joints were purchased from Articular Engineering
(Northbrook, IL, USA). A full-thickness cylindrical incision in the cartilage segment of the osteochondral explant was created by a 4 mm biopsy punch (Integra™
Miltex®, USA). Following incision, the osteochondral explants were categorized as (a) Control (No cytokine or
no-cLIUS stimulation) (b) cLIUS (c) IL-6 (d) cLIUS
+IL-6 (e) TNFα (f ) cLIUS+ TNFα with each study group
consisting of at least 12–20 explants. The study design is
schematically depicted in Fig. 1. The culture media for
explants was DMEM-F12 supplemented with 10%
FBS, 1× antibiotic-antimycotic solution (Gibco, USA)
and 50 μg/ml ascorbic acid. IL-6 or TNFα (R&D Systems, Minneapolis, MN) was added to appropriate
wells at 20 ng/ml concentration as IL-6 or TNFα
dosage of 10–25 ng/ml demonstrated enhanced catabolic effects in chondrocyte cultures [16, 17]. All explants were placed in 6-well ultra-low attachment
tissue culture plates (TCPs) and were either incubated in a CO2 incubator (37 °C, 5% CO2) or were
cultured in the ultrasound-assisted bioreactor developed at UNL for 28 days. Media were replenished
every 2 days. Sampling for outcome analyses was
done on day 14 and day 28 of culture.
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Fig. 1 Schematic representation of the repair of chondral fissures by cLIUS under catabolic conditions: (a) Figure represents a schematic model of
chondral fissures in bovine osteochondral explants. A 4 mm full-thickness concentric incision in the cartilage portion of the osteochondral
explants (8 mm diameter, 1-2 mm chondral thickness, 1-5 mm bone segment) was created using a biopsy punch. b Experiment design: The
incised osteochondral explants were cultured in DMEM-F12 medium supplemented with 10% FBS, 1× antibiotic-antimycotic solution and 50 μg/
ml L-ascorbic acid without any cytokine treatment or in the presence of either IL-6 or TNFα, each added at a concentration of 20 ng/ml. cLIUS
was applied at 14 kPa (5 MHz, 2.5 Vpp), 20 min, 4times/day for 28 days. Non-cLIUS-stimulated explants served as controls for each
treatment condition

Bovine articular chondrocyte culture

Cell viability assay

Bovine articular chondrocytes were isolated from stifle joints
as described elsewhere [18] and cultured in DMEM-F12 supplemented with 10% FBS, 1× antibiotic-antimycotic solution
(Gibco, USA) and 50 μg/ml ascorbic acid in 6 well TCPs for
quantitative real time polymerase chain reaction (qRT-PCR)
and scratch assays. The wells (n = 3 per group) were categorized as (a) Control (No cytokine or cLIUS treatment) (b)
cLIUS (c) IL-6 (d) cLIUS+IL-6 (e) TNFα (f) cLIUS+ TNFα
and incubated in a CO2 incubator (37 °C, 5% CO2). IL-6 or
TNFα (20 ng/ml) was added to appropriate wells.

Cell viability was assessed by Live/Dead Viability/Cytotoxicity kit (Molecular Probes, USA) in the osteochondral
explants of each group (n = 3 per group per time point) on
day 3 and 21 of culture. The explants were incubated with
6 μM calceinAM and 4 μM ethidium homodimer-1 solution
for 1 h at 37 °C under aseptic conditions and visualized by
confocal microscopy (Olympus 1× 81) at 10× magnification
(z step size = 5 μm, 30–40 slices per sample, ~ 150-200 μm
deep) from the top or superficial zone of cartilage at the
interfacial region.
Histology and immunohistochemistry

cLIUS treatment

cLIUS (< 20 mW cm− 2) treatment was conducted in a
custom-designed ultrasound-assisted bioreactor developed and characterized at the Department of Chemical
and Biomolecular Engineering, UNL, USA, with operating procedures described elsewhere [15, 19]. cLIUS was
applied to explants at 5 MHz at a constant pressure
amplitude of 14 kPa at input voltage of 2.5 Vpp (peakto-peak voltage) for 20 min per application and 4 applications per day for a period of 28 days. In a separate
experiment, explants were exposed to cLIUS at 2 MHz,
a frequency outside the resonant bandwidth [13], for a
period of 14 days (n = 6) in the cLIUS-assisted bioreactor
at the constant pressure amplitude of 14 kPa (6.0 Vpp,
20 min per application,4 applications/day). For adherent
chondrocyte cultures, cLIUS was applied using nonfocused immersion transducers (Panametrics V300, 12.7
mm diameters, Panametrix, Waltham, MA, USA) at 5
MHz and 2.5 Vpp (or 14 kPa) for either 5 or 20 min.

Explants of each group (n = 6 per group) were typically
fixed in 10% neutral buffered formalin and decalcified
using a 1:1 ratio of 8% hydrochloric acid and 8% formic
acid solution. The explants were cut in half and each
half was paraffin embedded, sectioned and stained at the
Tissue Science Facility, University of Nebraska Medical
Center (Omaha, NE, USA) using standard protocol and
were reviewed by Dr. Steven H. Hinrichs (Professor,
Department of pathology and microbiology, UNMC,
Omaha, NE, USA). Histological staining with Alcian Blue
(pH 1) and Safranin O solution (Millipore, USA), and immunohistochemical staining with collagen II (ab34712, Abcam,
USA) were performed on deparaffinized sections (4 μm) and
visualized at 2× and 20× magnification. Normal bone tissue
sections served as negative control and normal colon tissue
served as positive control for collagen II staining. Fast green
(Millipore, USA) was used as a counterstain for Safranin O
staining. All sections were stained using the same staining solution and at the same time. Representative image of 18–36
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stained interfacial regions obtained from each group (n = 6)
was used.
Quantification of the interfacial apposition

Alcian blue stained explants were processed to quantify
percent apposition by measuring the length of the
bonded interfaces (no gaps) divided by the total length
of the interface [20]. Apposition was defined as the region along the interface that was bonded and did not
show any discernable gaps [21]. All measurements were
performed using histological images at 2× magnification
(n = 6) using ImageJ software.
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applied at 14 kPa (5 MHz, 2.5 Vpp) for 20 min to appropriate wells. The explants (n = 3 per group) were incubated with 6 μM calceinAM and 4 μM ethidium
homodimer-1 solution (Live/Dead Viability/Cytotoxicity
kit, Molecular Probes, USA) for 1 h at 37 °C on day 24
of culture. The central region of interest was imaged by
confocal microscopy (Olympus 1× 81) at 10× magnification (5 μm Z-size, 30–40 slices). Transmitted light
micrograph at 10× magnification was included to distinguish hydrogel region of the construct from the native
cartilage.
Statistical analysis

Quantitative real-time PCR

Bovine articular chondrocytes were plated at an initial seeding density of 2 × 105 cells/well. cLIUS was applied to appropriate wells for 5 min followed by homogenization with
Trizol. RNA was then extracted using RNeasy Mini Kit
(Qiagen, USA) as per the manufacturer’s protocol. Homogenates from 2 wells per group served as one replicate and 3
such replicates were used for analysis (n = 3). The qRT-PCR
analysis was carried out on Realplex™ real-time PCR system
(Eppendorf, USA) using TaqMan® RNA-to-CT™ 1-Step Kit
(Life Technologies) as per manufacturer’s guidelines. TaqMan®
probes and primers (Life Technologies, USA) used are as follows: GAPDH (Bt03210917_g1), MMP13 (Bt03214050_m1),
ADAMTS4 (Bt03224697_m1), NF-κB (Bt03243457_m1), Collagen II (Bt03251861_m1) and TIMP1 (Bt03223720_m1). The
expression of mRNA transcripts was normalized to GAPDH
expression and relative expression levels were calculated using
the 2-ΔΔCt method.
Scratch assay

Bovine articular chondrocytes were plated at a seeding
density of 1 × 105 cells per well (n = 3). Upon 90% confluency followed by serum starvation, a scratch representing a gap was created by a 200 μl pipette tip [11].
cLIUS was applied for 20 min to appropriate wells. Gap
area was imaged at 0 h, 6 h, 12 h, 24 h, 48 h and 72 h following the creation of scratch by bright field inverted
microscope at 5× magnification and the gap area covered by migrating cells was quantified by ImageJ.
Migration in cartilage-hydrogel constructs

To visualize the migration of cells in a 3D format, a 4
mm central chondral region was cored out of the osteochondral explant using a biopsy punch and filled with
sterile 1% agarose hydrogel. The cartilage-hydrogel constructs were categorized as (a) Control (No cytokine or
cLIUS treatment) (b) cLIUS (c) IL-6 (d) cLIUS+IL-6 (e)
TNFα (f ) cLIUS+ TNFα and cultured in DMEM-F12
supplemented with 10% FBS, 1× antibiotic-antimycotic
solution and 50 μg/ml ascorbic acid. IL-6 or TNFα was
added at a concentration of 20 ng/ml and cLIUS was

The data are represented as mean ± 95% confidence
interval where mean is calculated from 3 separate experiments, each conducted in triplicate per time point per
study group. For gene expression and percent apposition,
the statistical significance between the means of two groups
with unequal variance was calculated by Welch’s test. For
NF-κB gene expression, Welch’s analysis of variance
(ANOVA) was used to compare control, TNFα and cLIUS
+TNFα groups followed by post-hoc Games-Howell test for
pair-wise comparisons. For scratch assays, two-way ANOVA
with post-hoc Turkey’s test was used, and for cases where
variance homogeneity was violated, Welch’s ANOVA
followed by Games-Howell test was used for pair-wise comparisons. P values < 0.05 were considered significant and
exact p values were indicated in the figures.

Results
To understand the reparative and chondroprotective effects offered by cLIUS, the current study investigated
the repair of chondral fissures in bovine osteochondral
explants in the presence of catabolic cytokines IL-6 or
TNF-α as shown schematically in Fig. 1.
Cell viability around the chondral fissures

Cellular viability of the osteochondral explants in the vicinity
of the incision was examined by live-dead assay and shown in
Fig. 2. Cells surrounding the site of incision were predominantly live (green) interspersed with few dead (red) cells. On
day 3 of culture, chondral fissure was noticeable as a distinct
gap in all the explants (Fig. 2a-f). After 21 days in culture, explants that received cLIUS stimulation either in the presence
or absence of IL-6 or TNFα displayed enhanced cellular infiltration into the fissure when compared to non-cLIUS-stimulated controls (Fig. 2j-l).
Repair of chondral fissures under cLIUS

Explants were stained with alcian blue and shown in Fig. 3.
Explants that received cLIUS at 5 MHz displayed closed
fissures (Fig. 3d) on day 14 and a percent apposition of
58.04% (Fig. 4) was noted. In comparison, explants that received cLIUS at the non-resonant frequency of 2 MHz
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Fig. 2 Cell viability of explants. The viability of cells at the cartilage interfacial region at the vicinity of the chondral incision in osteochondral
explants was viewed by live-dead staining on day 3 and day 21 of culture. Explants (n = 3 per group) were incubated in 6 μM calceinAM and 4 μM
ethidium homodimer-1 solution for 1 h at 37 °C under aseptic conditions. Confocal micrographs viewed from the top or superficial zone of
cartilage depict live (green) cells and dead (red) cells at 10× magnification. White arrowheads indicate the leading edge of the chondral incision.
Scale bar represents 200 μm

displayed intact gaps (Additional file 1: Figure S1) along
with a percent apposition of 5.75% (Fig. 4). Percent apposition in non-cLIUS-stimulated explants at the end of 14
days was 3.32% (Fig. 4). Thus, subsequent experiments
examining the effect of cytokine on the closure of fissures
was performed at cLIUS at 5 MHz.
Explants that received cLIUS (5 MHz) in the presence
or absence of IL-6 or TNFα displayed closed gaps on day
14 (Fig. 3d-f) and day 28 of culture (Fig. 3j-l). In contrast,
non-cLIUS-stimulated explants and explants treated with
either IL-6 or TNFα alone displayed intact (Fig. 3a, b) or
partially narrowing fissures (Fig. 3c) on day 14, and closed

fissures on day 28 of culture (Fig. 3g-i). The quantification
of percent apposition corroborated the alcian blue staining
results and are shown in Fig. 4. On day 14 in the absence of
cytokine, the percent apposition was significantly (p = 0.027)
increased from 3.32% in non-cLIUS-stimulated control to
58.04% under cLIUS. The inclusion of cytokines in the culture
medium led to a higher percent apposition in non-cLIUSstimulated controls. The percent apposition remained significantly elevated under cLIUS when compared to noncLIUS-stimulated controls in the presence of IL-6 or
TNFα. On day 28 in the absence of cytokine, the percent
apposition was significantly higher in cLIUS-stimulated
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Fig. 3 Alcian blue staining of osteochondral explants. Incised osteochondral explants (n = 6 explants per group per time point) were grown in
DMEM-F12 medium supplemented with 10% FBS, 1× antibiotic-antimycotic solution and 50 μg/ml L-ascorbic acid in the presence or absence of
IL-6 or TNFα under cLIUS at 14 kPa (5 MHz, 2.5 Vpp), 20 min, 4 times/day. Non-cLIUS-stimulated explants (n = 6 explants per group per time point)
served as controls for each treatment condition. Explants were fixed in 10% neutral buffered formalin and embedded in paraffin. The panel shows
4 μm sections of osteochondral explants at the interfacial region stained with alcian blue (pH 1) after 14 and 28 days in culture at 20×
magnification. Scale bar represents 400 μm. Insets depict the whole section imaged at 2× magnification. Black arrows in the insets depict the
sites of incision

explants (p = 0.039) when compared to non-cLIUS-stimulated control. In contrast, no significant difference was noted
between cLIUS and non-cLIUS-stimulated explants in the
presence of either IL-6 or TNFα on day 28, corresponding to
closed fissures observed in Fig. 3 (h, i, k, l).
After 28 days, explants exposed to IL-6 alone displayed
weak alcian blue stain (Fig. 3h), indicating depletion of
proteoglycans. In contrast, intense alcian blue stain was
noted in IL-6-treated explants that received cLIUS
stimulation (Fig. 3k). Further analysis by safranin O
staining displayed noticeable depletion of proteoglycans
in explants treated with either IL-6 or TNFα alone

(Fig. 5b-c). cLIUS stimulation of IL-6 or TNFα-treated
explants showed an intense and homogenous Safranin O
stain (Fig. 5e-f ). Similarly, after 28 days in culture, immunohistochemical staining of explants for collagen II
exhibited weaker staining in non-cLIUS stimulated explants in the presence or absence of IL-6 or TNFα
(Fig. 5g-i) when compared to cLIUS-stimulated explants
(Fig. 5j-l).
Taken together, the results indicated that cLIUS at 5
MHz closed chondral fissures while preserving the proteoglycan and collagen distribution in the presence of IL-6 or
TNFα; thus, demonstrating a chondroprotective effect.
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Fig. 4 Percent apposition under cLIUS The length of chondral
interfaces in the cartilage and osteochondral explants (n = 6 per
sample per group per time point) were measured by ImageJ and
the percent apposition (closed gaps) was calculated as follows:
(length of closed interface/total length of interface) *100. Graph
represents the percent apposition in non-cLIUS-treated and cLIUSstimulated explants in the presence or absence of IL-6 or TNFα in
osteochondral explants on day 14 and 28 of culture. Data represents
a mean ± standard deviation. Statistically significant differences are
indicated by p-values and non-significant differences are indicated
as n.s
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discernable differences in NF- κB gene expression were
noted when chondrocytes were exposed to IL-6 (Fig. 6c).
Under cLIUS, the gene expression of NF- κB was suppressed in chondrocytes exposed to TNFα (0.75 ± 0.13-fold
in cLIUS+ TNFα versus 1.44 ± 0.03-fold in TNFα,
p = 0.046) (Fig. 6c).
The gene expression of the cartilage-specific marker, collagen II, remained significantly elevated (5.85 ± 0.57-fold
p = 0.004 versus non-cLIUS-stimulated control) under cLIUS
stimulation irrespective of IL-6 (5.88 ± 0.95-fold in cLIUS
+IL-6 versus 0.89 ± 0.07-fold in IL-6; p = 0.009) or TNFα
treatment (5.01 ± 0.41-fold in cLIUS+TNFα versus 0.63 ±
0.11-fold in TNFα; p = 0.003) (Fig. 6d). Significant increases
(3.15 ± 1.10-fold in cLIUS+TNFα versus 0.61 ± 0.30-fold in
TNFα, p = 0.038) in the gene expression of TIMP1, an anabolic inhibitor of metalloproteinases, was observed when
IL-6-treated chondrocytes were exposed to cLIUS (Fig. 6e).
TNFα treatment had no significant effect on the gene expression of TIMP1 with or without cLIUS stimulation.
The results indicated that the catabolic genes were
downregulated under cLIUS and this downregulation
was sustained in the presence of pro-inflammatory cytokines IL-6 and TNFα. In addition, cLIUS stimulation
demonstrated elevated levels of anabolic genes regardless
of cytokine treatment.

Gene expression profile under cLIUS

Migration of cells under cLIUS

To further ascertain the chondroprotective effect of cLIUS,
the expression of select catabolic (MMP13, ADAMTS4) and
anabolic genes (Collagen II and TIMP1) were evaluated in
cultured chondrocytes by qRT-PCR and shown in Fig. 6.
The expression of the transcription factor (NF-κB) in regulating the expression of catabolic genes was also assayed. In
the absence of any cytokine insult, the exposure of chondrocytes to cLIUS reduced the gene expression of MMP13
(p = 0.037) and ADAMTS4 (p = 0.001) when compared to
non-cLIUS-stimulated controls (indicated by rectangle in
Fig. 6a, b). The inclusion of IL-6 or TNFα significantly
elevated the gene expression of MMP13 (10.48 ± 7.43-fold in
IL-6 and 3.55 ± 1.07-fold in TNFα) and ADAMTS4 (92.26 ±
61.10-fold in IL-6; 2.26 ± 0.46-fold in TNFα) in non-cLIUSstimulated chondrocytes (indicated by open arrows in
Fig. 6a, b). Whereas, cLIUS diminished the IL-6 or
TNFα-induced upregulation of the catabolic markers
(p = 0.038 in cLIUS+IL-6 versus IL-6, and p = 0.004 in
cLIUS+TNFα versus TNFα for MMP13; p = 0.049 in cLIUS
+IL-6 versus IL-6, and p = 0.036 in cLIUS+TNFα versus
TNFα for ADAMTS4), and returned the gene expression
to baseline levels observed under cLIUS-stimulation only
(indicated by closed arrows in Fig. 6a, b). As anticipated,
the exposure of chondrocytes to TNFα led to an increase in
the gene expression of NF-κB (1.44 ± 0.03-fold in TNFα
versus 1.01 ± 0.01-fold in control, p = 0.019) while no

Increasing the availability of cells for migration at the
wound edge has been shown to improve integration of
cartilage surfaces [21, 22]. Therefore, cellular migration
under cLIUS in the presence of IL-6 or TNFα was studied in 2D and 3D formats. Migration of cells from the
surrounding cartilage tissue into the cell-free central
hydrogel core in cartilage-hydrogel constructs was visualized by live (green)/dead (red) staining and presented
in Fig. 7 under different treatment conditions. On day
24, an enhanced cell migration to the hydrogel core was
noted in all constructs that received cLIUS stimulation
irrespective of IL-6 or TNFα treatment (Fig. 7d-f ).
To better explain the results observed in 3D format in Fig. 7, a 2D scratch was employed to study
the migration of adult chondrocytes under cLIUS
stimulation in the presence or absence of IL-6 or
TNFα and is shown in Fig. 8a. After 48 h of cLIUS
stimulation, the migration of chondrocytes was significantly increased in the presence or absence of
IL-6 or TNFα, as evidenced by 55.27 ± 5.07%, 78.94
± 1.65%, and 38.96 ± 3.89% coverage of the scratch
area in cLIUS, cLIUS+IL-6, and cLIUS+TNFα samples, respectively (indicated by black arrows in
Fig. 8b-d). In contrast, the scratch area covered in
non-cLIUS stimulated, and chondrocytes treated
with IL-6 or TNFα alone was significantly reduced
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Fig. 5 Safranin O and collagen II staining of osteochondral explants. Incised osteochondral explants cultured for 28 days under cLIUS at 14 kPa (5
MHz, 2.5 Vpp), 20 min, 4 times/day in the presence or absence of IL-6 or TNFα (n = 6 explants per group). Non-cLIUS-stimulated explants served
as controls (n = 6 explants per group). Explants fixed in 10% neutral buffered formalin were paraffin embedded. The panel shows 4 μm sections of
osteochondral explants at the interfacial region stained with safranin O (a-f) and collagen II (g-l) at 20× magnification. Scale bar represents
400 μm. Insets depict the whole section imaged at 2× magnification. Black arrows in the insets depict the sites of incision

to 28.53 ± 4.94%, 22.62 ± 18.39% and 11.99 ± 2.67%
respectively.

Discussion
Cartilage repair protocols that promote integration with
the native tissue while mitigating the catabolic effects of
a pro-inflammatory environment and maintaining the
cartilage phenotype are of interest. The negative effects
of catabolic cytokines on cartilage have been well documented [23], however, to our knowledge studies demonstrating repair of cartilage fissures in a catabolic
environment, albeit in vitro, has not been reported. Elevated levels of IL-6 and TNFα in the injured cartilage
were implicated in the IL-6 and TNFα-mediated cartilage degradation [7]. Moderate dynamic compression and

pLIUS was previously shown to mitigate the cytokineinduced catabolic effects [11, 17] in cartilage explants via
the suppression of NF-κB. Our study combines an established in vitro cartilage integration model with catabolic
conditions imparted by IL-6 or TNFα and demonstrates
that when compared to non-cLIUS-stimulated explants: (1)
chondral fissures were repaired expeditiously by cLIUS at 5
MHz in the absence of cytokines; (2) the expeditious repair
of chondral fissures by cLIUS at 5 MHz was further
achieved in the presence of IL-6 and TNFα; (3) IL-6 and
TNFα-induced catabolic effects on cartilage was rescued by
cLIUS. In explants exposed to cLIUS applied at the
non-resonant frequency of 2 MHz, the chondral fissures
remained open and the percent apposition was not significantly different from non-cLIUS-stimulated controls.
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Fig. 6 qRT-PCR analysis of the catabolic and anabolic gene expression in chondrocytes. Bovine articular chondrocytes cultured in DMEM-F12
medium supplemented with 10% FBS, 1× antibiotic-antimycotic solution and 50 μg/ml L-ascorbic acid at an initial seeding density of 2 × 105
cells/well were subjected to cytokine treatment (n = 3) followed by cLIUS stimulation at 14 kPa (5 MHz, 2.5 Vpp) for 5 min. Non-cLIUS-stimulated
explants served as controls (n = 3). Homogenates from 2 wells per group served as one replicate and 3 such replicates were used for analysis
(n = 3). Total RNA was extracted and the gene expression of (a) MMP13, (b) ADAMTS4, (c) NF-κB, (d) Collagen II and (e) TIMP1 was evaluated by
qRT-PCR. Bar graph represents mean ± 95% confidence interval, p values indicate statistically significant differences and n.s represents
non-significant differences

Fig. 7 Cell migration to the hydrogel core from the surrounding cartilage in cartilage-hydrogel constructs. A 4 mm chondral core in
osteochondral explants was excised using a biopsy punch and filled with cell-free 1% agarose hydrogel to form cartilage-hydrogel constructs and
cultured in DMEM-F12 medium supplemented with 10% FBS, 1× antibiotic-antimycotic solution and 50 μg/ml L-ascorbic acid for 24 days in the
presence or absence of IL-6 or TNFα. Constructs (n = 3) were exposed to cLIUS at 14 kPa (5 MHz, 2.5 Vpp), 20 min, 4 times/day (d-f). Non-cLIUSstimulated constructs (n = 3) served as controls (a-c). Confocal micrographs demonstrate infiltrated cells from the surrounding cartilage into the
hydrogel core when stained with 6 μM calceinAM (green) and 4 μM ethidium homodimer-I (red) on day 24 of culture. Live cells are represented in
green and yellow arrows indicate the direction of the migration of cells from the surrounding cartilage to the hydrogel core. Yellow dotted line
shows the boundary between the hydrogel core and the surrounding cartilage. Transmitted light micrographs shows the phase-contrast image
of hydrogel-cartilage constructs. Scale bar represents 100 μm
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Fig. 8 Migration of chondrocytes under cLIUS and cytokines as measured in scratch assays. a The figure depicts phase contrast micrographs of
the scratch area of chondrocytes at 12, 48 and 72 h (n = 3 scratch areas in 3 separate wells, 5× magnification; scale bar = 100 μm) in the presence
or absence of IL-6 or TNFα under cLIUS at 14 kPa (5 MHz, 2.5 Vpp) for 20 min. Non-cLIUS-stimulated chondrocytes served as control (n = 3 scratch
areas in 3 separate wells). Percentage scratch area closed by migrating chondrocytes at 6, 12, 24, 48 and 72 h normalized to the wound area at 0
h under no cytokine (b), IL-6 (c) and TNFα (d) were quantified by ImageJ software. Data represented as mean ± 95% confidence interval

Most pharmacological interventions that employ
anti-cytokine agents such as receptor antagonists for
IL-1β, IL-6 or TNFα [24–26] and chondroprotective
drugs [27, 28], are target-specific, abrogating the effect
of a particular cytokine [7, 8]. However, targeting an
individual cytokine may not be sufficiently effective
in reducing the overall inflammatory response. Further, toxicity and adverse side-effects associated with
the administration of anti-inflammatory agents hinder their long-term clinical usage [10]. Thus, a treatment modality that attenuates the effects of potent

pro-inflammatory cytokines is required. The current
study demonstrated the ability of cLIUS in suppressing the effects of two potent catabolic cytokines
namely IL-6, and TNFα.
The expression of catabolic enzymes MMPs and ADAMTs
that degrade collagens and aggrecanases respectively are elevated in injured cartilage [7, 29], and the catabolic response
upon injury is exacerbated by the synergistic effects conferred by the pro-inflammatory cytokines including IL-6 and
TNFα [9, 29]. In an environment of accelerated matrix degradation, the anabolic response to synthesize matrix falls
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behind [30, 31] and is often suppressed upon pathological
progression. Thus, increased matrix turnover to overcome
catabolic effects in injured cartilage is desirable. Anti-inflammatory therapeutic agents, while noted to rescue cartilage
from proteoglycan loss under inflammation, do not have an
effect on anabolic gene expression [32, 33]. In the present
study, significant upregulation in the anabolic response of
chondrocytes as evidenced by 5.85-fold increases in
collagen II (Fig. 6d) and 3.15-fold increase in TIMP1 gene
expression under cLIUS (Fig. 6e) accompanied the downregulation of catabolic genes, MMP13 and ADAMTS4
upon cLIUS stimulation in the presence of IL-6 or TNFα
(Fig. 6a, b). Additionally, the expression of anabolic genes
observed under cLIUS was consistent with the higher intensity of collagen and proteoglycan staining noted in explants (Fig. 5d-f, j-l). Collectively, cLIUS elicited a
coordinated response that promoted cartilaginous matrix
synthesis while simultaneously protecting the matrix from
IL-6 or TNFα –induced degradation.
The key transcription factor, NF-κB, regulates inflammation by inducing the expression of pro-inflammatory
cytokines and mediators, including TNFα which in turn
potentiates activation of NF-κB [34, 35]. The inhibition
of TNFα-induced upregulation of NF-κB by cLIUS in
the present study (Fig. 6c) demonstrated the effective
modulation of the NF-κB inflammation pathway in
chondrocytes by cLIUS. Evidence of complete abrogation
of IL-1β –induced NF-κB activation upon LIUS stimulation in a previous study [11] lends further credence to
the overall anti-inflammatory effect of LIUS. Differently
from the NF-κB pathway, IL-6 induces the expression of
catabolic genes via the STAT3 pathway [36]. Therefore,
the expression of NF-κB remained unaffected by IL-6 insult in the present study. However, elevated levels of
TIMP1 expression may have rescued the IL-6-induced
catabolic effects when exposed to cLIUS (Fig. 6e).
In the local milieu of the inflamed joint, an increase in
the antagonistic factors that impede the migration of cells
to the injured site is counterproductive to integrative repair strategies [21, 22, 37, 38]. Among the plethora of chemokines released upon inflammation; some invoke
recruitment of resident and progenitor cells to initiate repair while others inhibit migration of cells. Notably, TNFα
has been implicated in impeding cell migration [39] while
IL-6 is known to support migration [40]. Both in the presence and absence of IL-6 or TNFα, an expeditious repair
of chondral fissures noted under cLIUS, was attributed to
the enhanced migration of cells.
Elongated cells were observed in TNFα-treated cartilagehydrogel constructs (Fig. 7c, f). The cause of altered cell
morphology observed is uncertain. Decreased hydrogel stiffness at lower concentrations of agarose (~ 1% agarose) was
shown to affect cell shape [41]. Also, progenitor cells often
display an elongated cell morphology [42] and are reported
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to possess greater migratory potential [43–45]. Thus, the
modified cellular morphology observed could be attributed
to a combination of factors, including the biophysical properties of the hydrogel and the nature of the migrating cells.
Therefore, further investigations centering on the identity of
migrating cells, morphological response to external physical
and chemical forces including cLIUS, cytokine and/or biomaterial will be undertaken in the future. Therapeutic doses
of cLIUS below 500 mW/cm2 do not have an adverse effect
on bone growth [46]. As the cLIUS regimen employed in
this study was less than < 20 mW/cm2, the impact of cLIUS
on the bone was not investigated. However, the impact of
cLIUS on both the bone and cartilage will be studied in future in vivo studies. Further, the thermal effects of cLIUS on
cartilage was also not investigated in the current study as
cLIUS intensity less than 20 mW/cm2 was not shown to
elicit any thermal effects [15].

Conclusions
Synergistic rehabilitative regeneration methods that overcome the adverse catabolic effects of the pro-inflammatory
joint environment while simultaneously promoting chondroregeneration are paramount to achieving joint restoration in
the long-term. Taken together [11], results demonstrated the
potential of cLIUS as a pro-anabolic, anti-catabolic and
chondroprotective therapy for applications in rehabilitative
regeneration programs for cartilage repair. The translation of
promising in-vitro finding regarding cLIUS necessitates an
understanding of the propagation of cLIUS through the joint
space, an ongoing study in our laboratory.
Additional file
Additional file 1: Figure S1. Alcian Blue staining of osteochondral
explants under cLIUS at 2 MHz. Incised osteochondral explants were
exposed to cLIUS at a non-resonant frequency of 2 MHz at 14 kPa
(6 Vpp), 20 min/application, 4 applications/day for a period of 14 days in
culture (n = 6). Non-cLIUS-stimulated explants served as controls (n = 6).
Explants were fixed in 10% neutral buffered formalin and embedded in
paraffin. Figure shows 4 μm sections of osteochondral explants at the
interfacial region stained with alcian blue (pH 1) after 14 days in culture at
20× magnification. Scale bar represents 100 μm. Inserts depict the whole
section imaged at 2× magnification. (TIF 9326 kb)
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